SCHEMBL13860745

SCHEMBL13860745

CC(=O)OCc1nc(-c2cnc(Cl)c(Cl)c2)no1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SIRT2 Q8IXJ6 1/20 0.51
MAPT P10636 5/20 0.46
GSTP1 P09211 4/20 0.45
L3MBTL1 Q9Y468 3/20 0.45
TDP1 Q9NUW8 2/20 0.45
ALDH1A1 P00352 1/20 0.45
NOTUM Q6P988 1/20 0.44
TSHR P16473 3/20 0.43
NPC1 O15118 3/20 0.43
RAB9A P51151 3/20 0.43
SMN1; SMN2 Q16637 3/20 0.43
LMNA P02545 3/20 0.43
TP53 P04637 1/20 0.43
HPGD P15428 1/20 0.43
NFKB1 P19838 1/20 0.43
CASP3 P42574 1/20 0.43
NFKB2 Q00653 1/20 0.43
RELA Q04206 1/20 0.43
SENP8 Q96LD8 1/20 0.43
SENP7 Q9BQF6 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5351217 0.82 SIRT2 (0.73) SIRT2MAPTGSTP1TDP1NOTUM
SCHEMBL13977860 0.79 NOTUM (0.48) L3MBTL1TDP1ALDH1A1NOTUMFFAR1
SCHEMBL16000805 0.78 ACACB (0.47) SIRT2MAPTL3MBTL1TDP1NOTUM
SCHEMBL24922866 0.78 SIRT2 (0.47) SIRT2MAPTGSTP1L3MBTL1TDP1
SCHEMBL19012092 0.75 ACLY (0.47) SIRT2MAPTGSTP1SMN1; SMN2LMNA
SCHEMBL13977988 0.73 GPR119 (0.46) GSTP1SMN1; SMN2
SCHEMBL8892261 0.73 LMNA (0.64) SIRT2MAPTL3MBTL1TDP1ALDH1A1
SCHEMBL24922901 0.72 NOTUM (0.44) SIRT2MAPTGSTP1L3MBTL1TDP1
SCHEMBL8889364 0.69 NPC1 (0.62) MAPTALDH1A1TSHRNPC1RAB9A
SCHEMBL7833034 0.69 CNR2 (0.48) ALDH1A1TSHRLMNAHPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2709609-B1 HETEROCYCLIC COMPOUNDS SHIONOGI & CO (JP) 2017-10-04 EP disclosed
EP-2709609-B1 HETEROCYCLIC COMPOUNDS SHIONOGI & CO (JP) 2017-10-04 EP disclosed
US-9156830-B2 Heterocyclic compounds SHIONOGI & CO., LTD. (JP) 2015-10-13 US disclosed
US-9156830-B2 Heterocyclic compounds SHIONOGI & CO., LTD. (JP) 2015-10-13 US disclosed
US-20140249159-A1 HETEROCYCLIC COMPOUNDS PURDUE PHARMA L.P. 2014-09-04 US disclosed
US-20140249159-A1 HETEROCYCLIC COMPOUNDS PURDUE PHARMA L.P. 2014-09-04 US disclosed
EP-2709609-A1 HETEROCYCLIC COMPOUNDS Shionogi & Co., Ltd. (JP) 2014-03-26 EP disclosed
WO-2012158844-A1 HETEROCYCLIC COMPOUNDS SHIONOGI & CO., LTD. (JP) 2012-11-22 WO disclosed
WO-2012158844-A1 HETEROCYCLIC COMPOUNDS SHIONOGI & CO., LTD. (JP) 2012-11-22 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140249159-A1 HETEROCYCLIC COMPOUNDS HRH2, UGT1A3, UGT1A1 SIRT2 754/4885MAPT 3166/4885GSTP1 3473/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.